Mystic Pharmaceuticals Receives US Patent For Novel Nose To Brain Delivery Of Therapeutics To Treat Neurodegenerative Disorders

AUSTIN, Texas--()--Mystic Pharmaceuticals, Inc., a privately held, life science technology company, announced today it has received a patent from the United States Patent Office for its “Dose Dispensing Containers” (US Patent 9,248,076 B2). Mystic’s latest innovation facilitates the development of non-invasive nose-to-brain delivery systems for drugs and biologics, to treat neurodegenerative disorders such as Parkinson’s, Alzheimer’s, seizures and traumatic brain injury.

“Nose to brain delivery is emerging as a viable means of non-invasive delivery of certain classes of drugs and biologics directly into the brain via the nose, while bypassing the blood brain barrier,” said Timothy Sullivan, Mystic’s Founder and co-inventor of the technology. “Our long-term vision is the development of patient-centric drug/device combination products that can safely and effectively be used directly by patients and caregivers to self-administer therapeutics for treating neurodegenerative diseases,” Mr. Sullivan stated.

These latest innovations extend the capabilities of Mystic’s VersiDoser® and VRx2™ packaging and delivery platforms enabling the development of new classes of innovative, value-add drug/device combination products and routes of non-invasive administration. Mystic’s engineered delivery platforms are used in combination with therapeutics for the treatment of ocular, CNS, neurodegenerative and infectious diseases affecting large global populations.

Mystic’s technology enables pharmaceutical and biotech manufacturers to develop drug/device combination products that can extend or establish market exclusivity and competitive differentiation for new or existing drugs and biologics. The shift to developing value-added, patient-centric products benefits the consumer through improved compliance and health outcomes while building brand value for the pharmaceutical manufacturer. Mystic’s delivery platforms and products are designed to meet the diverse demands of consumers and pharma manufacturers in globally competitive markets.

About Mystic Pharmaceuticals, Inc.

Mystic Pharmaceuticals® is a life science technology company based in Austin, Texas. Mystic provides patient-centric unit dose packaging and delivery technology for pharmaceuticals, biopharmaceuticals and biologics for intranasal, nose-to-brain, ophthalmic, sublingual, and otic product applications. For more information please visit the Mystic website at: http://www.mysticpharmaceuticals.com

Contacts

Mystic Pharmaceuticals, Inc.
Melissa Brandt, +1-512-918-2900
mbrandt@mysticpharmaceuticals.com

Release Summary

Mystic Pharmaceuticals Receives US Patent For Novel Nose To Brain Delivery Of Therapeutics To Treat Neurodegenerative Disorders

Contacts

Mystic Pharmaceuticals, Inc.
Melissa Brandt, +1-512-918-2900
mbrandt@mysticpharmaceuticals.com